Trials & R&D · first seen 1h ago, updated 1h ago
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipelin…
Summary from MedCity News.